Healthcare Jul 29, 2021 08:22 AM (GMT+8) · EqualOcean
29 million health experts said that Wuhan's Kangliu biologic (hereinafter referred to as "kanglibijing") has completed tens of millions of yuan in B+ round of financing, and has been invested by Chu Chang investment, Luojia Wutong, and Hubei high tech investment group. Chen Gang, founder and CEO of Kanglu biology, said that this round of financing will be used to continue to consolidate the global leading position of Kanglu biological fluorescence in situ hybridization (FISH) technology analysis platform and accelerate the R & D process of technology platform in fields such as blood tumor molecular diagnosis. Founded in 2013, Kanglu biology focuses on molecular diagnosis of major diseases and is committed to providing a complete set of rapid, automated and intelligent fluorescence in situ hybridization detection solutions. At present, it has many technical platforms, including rapid fish technology platform, PCR (mRNA) technology platform and so on. Kanglu biology is promoting the implementation of two automatic detection equipment in the field of solid tumors and blood tumors, and is expected to be put into the market as soon as the second half of the year. In terms of intelligence, at present, the platform mostly uses fluorescence microscope for manual interpretation, which has high requirements for doctors. Kanglu biology plans to replace fluorescence microscope with automatic fluorescence microscope scanning technology equipment, and cooperate with intelligent auxiliary diagnosis function to help solve the problems faced by doctors. In the fields of blood tumors, Kanglu biology is not only using the rapid fish technology platform to detect the main targets, but also expanding a new product line to provide more products for clinic. In the planning of Kanglu biology, it is expected to achieve a breakthrough of 200-300 million sales in the next 2-3 years.

This text is a result of machine translation.